- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Tagrisso adjuvant lung cancer US Priority Review
AnnouncementREG - AstraZeneca PLC - Forxiga HF receives positive CHMP opinion
AnnouncementREG - AstraZeneca PLC - Trixeo Aerosphere receives positive CHMP opinion
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - COVID-19 antibodies advance and get US funding
AnnouncementREG - Circassia Group Plc AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Farxiga granted US BTD in chronic kidney disease
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Lynparza EU recommendation in prostate cancer
AnnouncementREG - AstraZeneca PLC - Tagrisso reduced early lung cancer brain recurrenc
AnnouncementREG - AstraZeneca PLC - Lynparza EU recommendation in ovarian cancer
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - AstraZeneca to list all US securities on Nasdaq
AnnouncementREG - AstraZeneca PLC - Fasenra PhIII OSTRO trial met co-primary endpoints
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Farxiga reduces CKD progression and risk of death
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for small cell lung cancer
AnnouncementREG - AstraZeneca PLC - Ph I trial begins for COVID-19 monoclonal antibody
Announcement